Researchers at the University of Cambridge have developed a potential new therapy for B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer. In lab models, it showed powerful effects — targeting cancer cells while potentially reducing the harsh side effects of chemotherapy.
A New Twist on Two Existing Drugs
The treatment uses two oral drugs — venetoclax and inobrodib — in a unique combination that attacks leukemia cells in tandem.
What Is B-ALL?
B-ALL is an aggressive blood cancer caused by immature B-cells that crowd the bone marrow and disrupt the production of healthy blood cells.
Chemotherapy Works, But at a High Cost
Standard treatment spans over two years and brings intense side effects like hair loss, infections, nerve damage, and long-term health risks.
Older Patients Face Worse Outcomes
While young children respond well to treatment, teenagers and adults often have lower survival rates and endure more complications.
Venetoclax Alone Isn’t Enough
This drug targets a key protein (BCL2) in leukemia cells, triggering cell death — but many B-ALL cases resist this approach on its own.
Inobrodib Changes the Game
Inobrodib turns off a gene called CREBBP, which rewires how leukemia cells use fat — making them more vulnerable to treatment.
Dual Attack on Leukemia Cells
The drug duo induces a unique kind of cell death called ferroptosis — destroying cells by damaging the fat layers in their membranes.
Works Even on Resistant Cells
The treatment showed success even against B-ALL cells that had previously been resistant to standard therapies.
Proven Safety in Other Trials
Both drugs have already been tested together in early-stage clinical trials for a different leukemia type, with promising safety data.
Clinical Trials on the Horizon
Cambridge researchers hope to begin trials in teens and adults soon, aiming to offer a gentler, more targeted alternative to chemotherapy.
Article Based on Information From Eurekalert